Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 128Breast Neoplasms 111Neoplasms 93Neoplasm Metastasis 76Melanoma 70Colorectal Neoplasms 69Leukemia, Myeloid, Acute 66Prostatic Neoplasms 58Multiple Myeloma 52Lung Neoplasms 51Ovarian Neoplasms 49Squamous Cell Carcinoma of Head and Neck 45Recurrence 41Triple Negative Breast Neoplasms 40Carcinoma, Renal Cell 38Carcinoma, Hepatocellular 38Pancreatic Neoplasms 36Myelodysplastic Syndromes 36Glioblastoma 34Brain Neoplasms 34Stomach Neoplasms 30Lymphoma, Non-Hodgkin 30Lymphoma 30Endometrial Neoplasms 30Head and Neck Neoplasms 28Lymphoma, Large B-Cell, Diffuse 27Leukemia 27Uterine Cervical Neoplasms 26Cholangiocarcinoma 26Urinary Bladder Neoplasms 24

Interventions

Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Endometrial Cancer Recurrent × 1 year × Clear all
NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

National Cheng-Kung University Hospital

Phase 2 Terminated
40 enrolled
Gynecologic

Endometrial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡